Gopal S. Patel

Nivagen is engaged in the development, acquisition, and sales of generic prescription drugs and over the counter products for the North American market. It envisions to deliver high-quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.The US genericprescription market is currently at approximately $60 billion, and over $120 billion's worth of products will be coming off of patent protection in the next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, they can provide cost savings to the consumer while creating value for all members of the supply chain.